Richard Stewart - Achieve Life Chairman of the Board, CEO
| ACHV Stock | USD 3.00 0.07 2.28% |
Chairman
Mr. Richard Stewart is Chairman of the Board, Chief Executive Officer and Director of the Company, since August 2017. Prior to our merger with Achieve Life Science, Inc., or the Merger, Mr. Stewart served as Chairman and as a director of Achieve Life Science, Inc. since it was founded in May 2015. Mr. Stewart is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart was Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinsons disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single purpose central nervous system company, during 2009, prior to Huxley Pharmaceuticals, Inc.s acquisition by BioMarin Pharmaceutical Inc. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single purpose central nervous system company, from 2013 to 2014. He was a cofounder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinsons disease and Huntingtons disease, from 2000 to 2007. Mr. Stewart was a cofounder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998 since 2017.
| Age | 66 |
| Tenure | 8 years |
| Address | 1040 West Georgia Street, Vancouver, BC, Canada, V6E 4H1 |
| Phone | 604 210 2217 |
| Web | https://www.achievelifesciences.com |
Richard Stewart Latest Insider Activity
Tracking and analyzing the buying and selling activities of Richard Stewart against Achieve Life stock is an integral part of due diligence when investing in Achieve Life. Richard Stewart insider activity provides valuable insight into whether Achieve Life is net buyers or sellers over its current business cycle. Note, Achieve Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell Achieve Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Richard Stewart over six months ago Disposition of 10125 shares by Richard Stewart of Achieve Life at 6.8 subject to Rule 16b-3 | ||
Richard Stewart over six months ago Acquisition by Richard Stewart of 6000 shares of Kirby at 99.52 subject to Rule 16b-3 | ||
Richard Stewart over six months ago Disposition of 2817 shares by Richard Stewart of Eagle Materials subject to Rule 16b-3 | ||
Richard Stewart over six months ago Acquisition by Richard Stewart of 140000 shares of Achieve Life subject to Rule 16b-3 |
Achieve Life Management Efficiency
The company has return on total asset (ROA) of (0.5409) % which means that it has lost $0.5409 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8604) %, meaning that it created substantial loss on money invested by shareholders. Achieve Life's management efficiency ratios could be used to measure how well Achieve Life manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Achieve Life's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 19.46 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.90). At this time, Achieve Life's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 35 K in 2025, whereas Other Current Assets are likely to drop slightly above 1.1 M in 2025.Similar Executives
| Found 5 records | CHAIRMAN Age | ||
| John CPA | Hepion Pharmaceuticals | 77 | |
| Sean DPHIL | CytomX Therapeutics | 58 | |
| Douglas Treco | Inozyme Pharma | 67 | |
| Dennis Lanfear | Coherus BioSciences | 70 | |
| Yves Sabbagh | Inozyme Pharma | N/A | |
Management Performance
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.54 |
Achieve Life Sciences Leadership Team
Elected by the shareholders, the Achieve Life's board of directors comprises two types of representatives: Achieve Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Achieve. The board's role is to monitor Achieve Life's management team and ensure that shareholders' interests are well served. Achieve Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Achieve Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cindy MD, Chief President | ||
| Jaime Xinos, Executive Commercial | ||
| Mark CPA, Chief Officer | ||
| Jerry Wan, Principal Officer | ||
| Anthony Clarke, President Chief Scientific Officer, Director | ||
| Richard Stewart, Chairman of the Board, CEO | ||
| John MBA, CEO Director | ||
| Thomas MBA, Executive Chairman | ||
| Craig Donnelly, Executive CMC | ||
| Mark Rubinstein, Head Affairs |
Achieve Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Achieve Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 72.51 M | ||||
| Shares Outstanding | 34.39 M | ||||
| Shares Owned By Insiders | 9.72 % | ||||
| Shares Owned By Institutions | 59.64 % | ||||
| Number Of Shares Shorted | 3.81 M | ||||
| Price To Earning | (0.03) X | ||||
| Price To Book | 3.36 X | ||||
| EBITDA | (26.73 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Achieve Stock Analysis
When running Achieve Life's price analysis, check to measure Achieve Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Achieve Life is operating at the current time. Most of Achieve Life's value examination focuses on studying past and present price action to predict the probability of Achieve Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Achieve Life's price. Additionally, you may evaluate how the addition of Achieve Life to your portfolios can decrease your overall portfolio volatility.